Narcolepsy with cataplexy after A/H1N1 vaccination – A case reported from Cuba  by Mesa, Yaimi Rosales & Meira e Cruz, Miguel Gonçalves
H O S T E D  B Y
Available online at www.sciencedirect.comwww.elsevier.com/locate/ssci
S l e e p S c i e n c e 7 ( 2 0 1 4 ) 5 9 – 6 1http://dx.doi.org
1984-0063/& 201
NC-ND license (
nCorrespondin
E-mail addresCase ReportNarcolepsy with cataplexy after A/H1N1 vaccination –
A case reported from CubaYaimi Rosales Mesa, Miguel Gonc¸alves Meira e Cruzn
Portuguese Association of Chronobiology and Sleep Medicinea r t i c l e i n f o
Article history:
Received 31 October 2013
Accepted 28 December 2013
Available online 22 August 2014
Keywords:
Narcolepsy
hypersomnolence
cataplexy
H1N1 vaccination/10.1016/j.slsci.2014.07.024
4 Brazilian Association of Sle
http://creativecommons.org/
g author.
s: mmc@gentesaudavel.pt (Ma b s t r a c t
Narcolepsy with cataplexy is a rare sleep disorder with a neurological basis which has been
recently linked to H1N1 vaccination either in children or adults. Cases from Europe, United
States and Brasil were registered. Authors describe a case report of a 15 years old boy who
developed narcolepsy with cataplexy after H1N1 vaccination in Havana. As far as it is
concerned this is the ﬁrst case reported from Cuba.
& 2014 Brazilian Association of Sleep. Production and Hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Narcolepsy with cataplexy is the most common type of
central hypersomnia and is usually deﬁned as a syndrome
characterized by excessive daytime sleepiness (EDS), cata-
plexy, hypnagogic or hypnopompic hallucinations, sleep
paralysis and disturbed nocturnal sleep [1].
Inability to remain fully alert is frequently the major problem
for narcoleptic patients, which persistently affects their lives on a
daily basis. Paradoxically adequate nighttime sleep continuity is
not easy to achieve for those individuals [2]. Also not necessarily
present, narcolepsy often occurs with a transient loss of muscle
tone triggered by emotional stimuli (catapletic attack). Therefore,
diagnosis is based on clinical criteria conﬁrmed by polysomno-
graphic study followed by amultiple sleep latency test (MSLT) [3].
Although it can affect any age, the peak age of onset is the
second decade of life with a reported incidence of 3.84/100,000
person years [4]. Narcolepsy onset is rare after age of 55 or prior
to age 10 [5] but the interval between onset and diagnosis can be
longer than 10 years [6], making it sometimes difﬁcult toep. Production and Hosti
licenses/by-nc-nd/3.0/).
.G. Meira e Cruz).establish the exact time of onset. Diagnostic delay is however
less common when cataplexy is present and in younger patients
[7]. Hypocretin, a neuropeptide originating from the hypothala-
mus, has been involved in the pathogenesis of narcolepsy with
lower or undetectable levels of cerebrospinal ﬂuid hypocretin-1
in most narcoleptic patients with cataplexy. Furthermore, there
is a strong association with human leukocyte antigen (HLA)
DQB1n0602, which is involved in the control of the hypocretin
receptor. More recently, associations with environmental factors
such as streptococcal infection [8], seasonal inﬂuenza [9] and A/
H1N1 2009 inﬂuenza [10] were reported and studied.
Authors describe a patient with narcolepsy with cataplexy
after A/H1N1 vaccination in Hospital Almeijeiras in Havana
as this is the ﬁrst known case reported from Cuba.2. Case report
A 15-year-old boy complaining of unexplained fatigue was ﬁrst
attended by the pediatrics ofﬁce on November 2010. Suchng by Elsevier B.V. This is an open access article under the CC BY-
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against the 2009 pandemic inﬂuenza A/H1N1 virus with Pan-
demrix™. Physical and neurological examinations were both
negative and, at this time, pediatrician hypothesized secondary
hypothyroidism which was not conﬁrmed. By August, he gained
additional 15 kg due to increased appetite including food inges-
tion during the night time and early in the morning. Two
months later (October) he presented with sleep attacks during
classes and poor sleep complains and after another two months
(by December) he started showing a loss of muscular tone ﬁrst
affecting the perioral and periocular region, complaining of
difﬁculties when trying to talk.
These sensations often occurred with dizziness and were
interpreted as pretenses by his teachers and thus were subject to
reprimand. These attitudes had forced him to change school.
There were subsequent changes in his mood with a somewhat
depression-like symptoms. There was no evidence of sleep
paralysis, hallucinations or any other sleep disturbance. Skull
magnetic resonance imaging and thyroid laboratory tests were
all normal.
Polysomnographic study was performed in February 2011
disclosing a total sleep time of 7 h 35min with sleep efﬁciency
of 93.7% and a sleep latency of two minutes and the ﬁrst period
starting in REM sleep with an absence of any other prevalent
pathologic ﬁndings as sleep-related breathing disorders or peri-
odic limb movements. The MSLT immediately after the PSG test
documented 4 sleep onset rapid eye movement periods (SOR-
EMPs) with latencies up to 5min (1.31min in average). Identiﬁ-
cation of HLA-DQ6 was made by the PCR-SSP technique in
February 2012. CSF hypocretin level could not be determined
because this test was not available at that time in our hospital.
Based on the clinical ﬁndings and objective measures it was
diagnosed as narcolepsy with cataplexy. The patient started
treatment with metilphenidate (10mg 3 times/day) for hyper-
somnolence. Despite subjective improvement on daytime sleepi-
ness, a newMSLT in April 2011 showed no signiﬁcant differences
compared with the previous one. The patient was instructed to
follow some sleep hygiene important roles as regular schedules
and scheduled short naps in order to improve excessive sleepi-
ness and was advised to avoid situations, which may lead to
emotional stimulation and thus catapletic attacks. No pharma-
cologic treatment was initiated for cataplexy since related
symptoms were not severe and this was not a major concern
for the patient. In February 2012 the patient showed some worry
about side effects of metilphenidate like alopecia, sudoresis,
increased frequency of headaches and cutaneous irritation,
which led to the decision to abandon therapy. The patient is
now 18 years old and is studying in university completing the
ﬁrst year. As the major part of his classes is in the afternoon, he
can sleep at home during the morning. However, when
he has classes during themorning he often falls asleep. Teachers
are however aware of his condition. Currently he is followed in
the sleep consultation department of our hospital.3. Discussion
In 2010, ﬁrst cases about a possible relationship between
H1N1 ﬂu vaccination and narcolepsy with cataplexy werereported in the north of Europe [11]. Almost at the same time
additional cases were independently reported in France,
Canada and the United States [8] and by January 2011, there
were 162 reported cases of narcolepsy after vaccination with
Arepanrix™ [12]. Biological mechanisms behind this link are
not clear, but an immunitary response to the vaccine adju-
vant used in this patient is most likely since side effects
suggestive of strong immune stimulation were reported after
A/H1N1 vaccination, particularly with Pandemrix™ [13]. In
those cases reported in the literature the onset of symptoms
ranged from two days to ﬁve months after vaccination and
many of them received vaccines with ASO3 as an adjuvant,
which is the same adjuvant used in Pandmrix™. This sup-
ports the immunitary role and the link between vaccination
and development of narcolepsy symptoms. The present case
evolved after A/H1N1 vaccination with Pandemrix™. Diagno-
sis of narcolepsy was carried out according to the current
guidelines and the short time that elapsed between vaccina-
tion and emergence of the clinical symptomsmakes plausible
the hypothesis of a link between both events. One important
limitation of this work must be mentioned and it is regarding
the fact that a single case was presented and thus the
establishment of a probable association between H1N1 vac-
cination and narcolepsy can be indeed criticized with the
argument that it can conﬁgure a subjective inference. On the
other hand, it remains crucial to understand the widespread
distribution of this relationship around the globe as well as
its particular characteristics and mechanisms for what these
reports can be of major relevance.
As founded by other authors, post-vaccine narcolepsy is
more frequent than it was previously thought. Furthermore it
requires an early diagnosis in order to prevent hypocretiner-
gic neuronal damage, which will aggravate this peculiar and
highly debilitating sleep-related neurologic condition.
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